Haemonetics Corporation (HAE)

Return on equity (ROE)

Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019
Net income (ttm) US$ in thousands 117,558 126,574 128,277 136,566 115,401 95,759 86,047 67,706 43,375 22,593 31,243 64,488 79,469 108,134 106,147 95,532 76,526 79,737 41,363 22,603
Total stockholders’ equity US$ in thousands 959,959 943,319 893,660 864,616 817,997 775,979 729,009 770,423 749,424 730,775 698,549 677,080 731,670 719,152 667,923 608,569 587,109 574,580 583,754 590,966
ROE 12.25% 13.42% 14.35% 15.79% 14.11% 12.34% 11.80% 8.79% 5.79% 3.09% 4.47% 9.52% 10.86% 15.04% 15.89% 15.70% 13.03% 13.88% 7.09% 3.82%

March 31, 2024 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $117,558K ÷ $959,959K
= 12.25%

Haemonetics Corporation's return on equity (ROE) has shown fluctuations over the past few quarters. The ROE has generally been trending upwards from the end of 2020 to the middle of 2023, reaching a peak of 15.89% in September 2020. However, there was a slight decrease in ROE in the most recent quarter, dropping to 12.25%.

Overall, the ROE for Haemonetics Corporation has been relatively healthy, consistently above 10% in most periods. This indicates that the company has been generating a favorable return on shareholders' equity. It is essential to monitor these fluctuations in ROE to assess the company's efficiency in utilizing its equity to generate profits for its shareholders.


Peer comparison

Mar 31, 2024